Strengthening development
Dr Sonya Montgomery joined OSE Immunotherapeutics SA, based in Nantes, France, as Chief Development Officer.
ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 265 entries already.
Entries by Maren Kühr
New non-executive director for Nuclera
Cambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
New CEO completes management team
Kufstein-based Single Use Support appointed Darren Verlenden as CEO and strengthens leadership team.
New CEO appointed
Matt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.
Experienced CMO on board
The French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.
Aequorin: superior choice for GPCR calcium signalling
The study of G protein-coupled receptor (GPCR) signalling is crucial for understanding a wide range of physiological processes. Among the methods used to monitor calcium signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.
CEO and Chairman of the Executive Board
French Innate Pharma SA announced the appointment of Jonathan Dickinson as the Company’s newChief Executive Officer (CEO) and Chairman of the Executive Board. He succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.
IZB Start-up AATec Medical GmbH
AATec Medical was founded in 2022 and is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
Sustainable, automated, ULT storage
The volume of samples and drug products requiring -80°C storage continues to increase, and shows no sign of slowing down. For many organisations, meeting these growing ULT storage requirements is challenging. The sheer volume of samples necessitates extensive storage capacity, which demands significant space, substantial energy use, and intensive management. Centralising and automating sample storage can provide a comprehensive solution.
Pichia protein production
Recombinant protein production in Pichia typically relies on AOX1 promoter-driven expression using methanol for induction. However, some companies avoid methanol due to safety concerns or operational demands. VALIDOGEN’s unique AOX1 promoter variants enable methanol-free protein production at high space-time yields, offering advantages beyond safety. Latest case studies underscore the strength of this technology.